Mulakan
Pokethebear

AVEO missed earnings - kidney cancer treatment too thinly traded

Panjang
Pokethebear Telah dikemas kini   
NASDAQ:AVEO   None
Fibonacci Supply and Demand Beyond Technical Analysis oncology kidney pharmaceuticals pharmastocks clinical fullretracement NEW LOW entrypoint
2
0
fibonacci supplyanddemand beyondta oncology kidney pharmaceuticals pharmastocks clinical fullretracement new low entrypoint
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
Komen:
snapshot
Currently at 618fibretracement
Komen:
Full 241% retracement and bounce to 161%. Sign of bouncing cat?
Penafian

Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.